ID   CML-iPSCs Pt2-No.1
AC   CVCL_A4AA
DR   SKIP; SKIP003250
DR   Wikidata; Q105506697
RX   PubMed=29429960;
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A4AB ! CML-iPSCs Pt2-No.2
OI   CVCL_A4AC ! CML-iPSCs Pt2-No.3
OI   CVCL_A4AD ! CML-iPSCs Pt2-No.4
OI   CVCL_A4AE ! CML-iPSCs Pt2-No.6
OI   CVCL_A4AF ! CML-iPSCs Pt2-No.8
SX   Male
AG   22Y
CA   Induced pluripotent stem cell
DT   Created: 12-01-21; Last updated: 19-12-24; Version: 5
//
RX   PubMed=29429960; DOI=10.1016/j.stemcr.2018.01.015; PMCID=PMC5919294;
RA   Miyauchi M., Koya J., Arai S., Yamazaki S., Honda A., Kataoka K.,
RA   Yoshimi A., Taoka K., Kumano K., Kurokawa M.;
RT   "ADAM8 is an antigen of tyrosine kinase inhibitor-resistant chronic
RT   myeloid leukemia cells identified by patient-derived induced
RT   pluripotent stem cells.";
RL   Stem Cell Reports 10:1115-1130(2018).
//